MRI Tracking of SPIO- and Fth1-Labeled Bone Marrow Mesenchymal Stromal Cell Transplantation for Treatment of Stroke

Xiaolei Huang, Yang Xue, Jinliang Wu, Qing Zhan, Jiangmin ZhaoContrast 2019 · DOI

TL;DR

This paper introduces a novel method for long-term tracking of transplanted stem cells in stroke models using MRI. By genetically engineering bone marrow mesenchymal stromal cells (BMSCs) to express ferritin (Fth1), the researchers achieved stable and sensitive MRI signal detection, outperforming traditional SPIO labeling for monitoring cell survival and migration over extended periods.

What Problem Does This Paper Address?

Treating neurological disorders like stroke often involves transplanting stem cells, such as bone marrow mesenchymal stromal cells (BMSCs), with the hope that they will repair damaged neural tissue. However, a significant challenge is understanding where these transplanted cells go, how long they survive, and if they proliferate within the body. Current methods for tracking these cells are often invasive, lack sensitivity, or are not suitable for long-term monitoring. Superparamagnetic iron oxide (SPIO) particles have been used for MRI tracking, but their signal can diminish over time due to cell division and clearance by macrophages, limiting their utility for long-term studies. This paper aims to address this gap by developing and evaluating a more stable and sensitive method for tracking BMSCs in vivo.

Methods

The researchers employed a genetic engineering approach to label BMSCs. They used a lentiviral vector to introduce the gene for ferritin heavy chain 1 (Fth1) into rat BMSCs. Ferritin is an endogenous protein that can store iron and, when overexpressed, can create a detectable MRI signal.

Key methodological steps included:

  • BMSC Culture and Identification: Standard methods were used to isolate and culture BMSCs, with flow cytometry confirming their purity (high expression of CD44 and CD90, low CD34). Differentiation potential was also assessed.
  • Lentiviral Transduction: BMSCs were transduced with a lentiviral vector carrying the Fth1 gene. The efficiency of transduction was confirmed by observing GFP expression.
  • In Vitro Characterization:
    • Ferritin Expression: Western blotting and immunofluorescence were used to confirm Fth1 protein expression in the modified BMSCs.
  • Iron Uptake: Prussian blue staining was performed to assess the iron-storing capacity of Fth1-BMSCs, particularly after incubation with ferric ammonium citrate.
  • In Vitro MRI: Fth1-BMSCs and SPIO-labeled BMSCs were analyzed using MRI (T2WI and SWI) in vitro to assess their signal contrast.
  • In Vivo Stroke Model and Cell Transplantation:
    • A middle cerebral artery occlusion (MCAO) model was established in rats to induce focal cerebral infarction.
  • Fth1-labeled BMSCs and SPIO-labeled BMSCs were injected intravenously into the rats. A control group was also included.
  • In Vivo MRI Tracking: MRI scans (DWI, T2WI, and SWI) were performed at multiple time points (1, 10, 20, 40, and 60 days post-transplantation) to monitor the location and signal intensity of the labeled cells.
  • Histology: Prussian blue staining was performed on brain tissue sections to confirm the presence and distribution of iron-containing cells post-mortem.

Datasets

Not discussed in the paper. The study utilized in vitro cell cultures and in vivo animal models (Sprague Dawley rats) for its experiments.

Key Insights and Ideas

  • Ferritin as a Stable MRI Reporter: The study demonstrates that genetically engineered ferritin (Fth1) can serve as a stable and reliable endogenous reporter for long-term MRI tracking of transplanted BMSCs. Unlike SPIO particles, which can be diluted or cleared, the Fth1 gene is inherited by daughter cells, maintaining a consistent signal.
  • SWI Superiority for Tracking: Susceptibility-weighted imaging (SWI) proved to be significantly more sensitive than T2-weighted imaging (T2WI) for detecting both SPIO- and Fth1-labeled cells. SWI provided a longer and wider range of hypointense signals, making it the optimal sequence for this application.
  • Fth1-BMSCs Show Sustained Signal: Fth1-labeled BMSCs maintained a consistent MRI signal intensity from 10 to 60 days post-transplantation, highlighting the long-term traceability of this method. In contrast, SPIO-BMSC signals gradually reduced over time.
  • Iron Uptake and Storage: Fth1-BMSCs showed good iron uptake and storage capacity, visualized by Prussian blue staining, especially when supplemented with ferric ammonium citrate. This iron accumulation contributes to the MRI signal.
  • Cell Migration and Distribution: Both Fth1-BMSCs and SPIO-BMSCs were detected around and within the infarction area, indicating successful migration to the site of injury. The Fth1-BMSCs showed a steady signal in the SWI sequence up to 60 days, suggesting their presence and potential activity.

Key Results

  • Long-Term Tracking: Fth1-BMSCs provided a stable MRI signal for up to 60 days, whereas SPIO-BMSCs were traceable for a shorter duration (approximately 30 days in SWI).
  • Imaging Sequence Efficacy: SWI sequences showed hypointense lesions for both SPIO-BMSCs (up to 30 days) and Fth1-BMSCs (up to 60 days). T2WI was less sensitive, particularly for Fth1-BMSCs.
  • Cellular Presence: Prussian blue staining confirmed the presence of iron-containing cells (both Fth1- and SPIO-labeled) in the infarction area and center in both transplantation groups.
  • Safety and Reliability: Fth1-BMSCs were found to be safe and reliable for transplantation in the focal cerebral infarction model.
  • Metabolic Activity: Fth1-BMSCs exhibited slightly higher metabolic activity compared to control BMSCs, as assessed by CCK8 assay, suggesting no significant cytotoxicity from Fth1 expression.

Limitations and Future Work

  • Detection Threshold: The study acknowledges that current MRI technologies have limitations in detecting very low concentrations of iron. This might obscure subtle changes in cell numbers or activity at later time points.
  • Proliferation vs. Migration: While the sustained signal suggests cell presence, it's challenging to definitively distinguish between continued proliferation and stable engraftment/migration solely based on MRI signal intensity. The authors suggest that Fth1-labeling could potentially observe proliferation and differentiation, but further studies are needed.
  • Therapeutic Efficacy: While the study demonstrates the feasibility of tracking Fth1-BMSCs and notes a "marked beneficial effect," the primary focus was on the tracking methodology. Specifically designed studies are needed to fully characterize the therapeutic actions of Fth1-BMSCs.
  • Long-Term Safety and Differentiation: Further research is required to investigate the long-term safety and differentiation properties of Fth1-BMSCs in rat models.
  • Exploration of SPIO Signal Decline: The paper notes that the reason for the lower transverse relaxation and distribution of SPIO-BMSCs compared to Fth1-BMSCs needs further exploration.

Summary updated

Abstract

We aimed to identify a suitable method for long-term monitoring of the migration and proliferation of mesenchymal stromal cells in stroke models of rats using ferritin transgene expression by magnetic resonance imaging (MRI). Bone marrow mesenchymal stromal cells (BMSCs) were transduced with a lentivirus containing a shuttle plasmid (pCDH-CMV-MCS-EF1-copGFP) carrying the ferritin heavy chain 1 (<i>Fth1</i>) gene. Ferritin expression in stromal cells was evaluated with western blotting and immunofluorescent staining. The iron uptake of <i>Fth1</i>-BMSCs was measured with Prussian blue staining. Following surgical introduction of middle cerebral artery occlusion, <i>Fth1</i>-BMSCs and superparamagnetic iron oxide- (SPIO-) labeled BMSCs were injected through the internal jugular vein. The imaging and signal intensities were monitored by diffusion-weighted imaging (DWI), T2-weighted imaging (T2WI), and susceptibility-weighted imaging (SWI) <i>in vitro</i> and <i>in vivo</i>. Pathology was performed for comparison. We observed that the MRI signal intensity of SPIO-BMSCs gradually reduced over time. <i>Fth1</i>-BMSCs showed the same signal intensity between 10 and 60 days. SWI showed hypointense lesions in the SPIO-BMSC (traceable for 30 d) and <i>Fth1</i>-BMSC groups. T2WI was not sensitive enough to trace <i>Fth1</i>-BMSCs. After transplantation, Prussian blue-stained cells were observed around the infarction area and in the infarction center in both transplantation models. <i>Fth1</i>-BMSCs transplanted for treating focal cerebral infarction were safe, reliable, and traceable by MRI. <i>Fth1</i> labeling was more stable and suitable than SPIO labeling for long-term tracking. SWI was more sensitive than T2W1 and suitable as the optimal MRI-tracking sequence.
BibTeX
@inproceedings{huang2019mri,
  author = {Xiaolei Huang and Yang Xue and Jinliang Wu and Qing Zhan and Jiangmin Zhao},
  title = {{MRI Tracking of SPIO- and <i>Fth1</i>-Labeled Bone Marrow Mesenchymal Stromal Cell Transplantation for Treatment of Stroke}},
  booktitle = {Contrast},
  year = {2019},
  doi = {10.1155/2019/5184105},
}
Figure